NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Price Target & More

$17.00 +0.55 (+3.34 %)

(As of 04/24/2018 04:00 PM ET)

Previous Close$17.00

Today's Range$16.50 - $17.40

52-Week Range$15.66 - $48.87

Volume763,908 shs

Average Volume540,912 shs

Market Capitalization$566.78 million

P/E Ratio-3.16

Dividend YieldN/A

Beta3.41

About Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Receive FPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:FPRX

CUSIPN/A

Webwww.fiveprime.com

Phone415-365-5600

Debt

Debt-to-Equity RatioN/A

Current Ratio6.10%

Quick Ratio6.10%

Price-To-Earnings

Trailing P/E Ratio-3.16

Forward P/E Ratio-3.41

P/E GrowthN/A

Sales & Book Value

Annual Sales$39.51 million

Price / Sales15.11

Cash FlowN/A

Price / CashN/A

Book Value$7.80 per share

Price / Book2.18

Profitability

EPS (Most Recent Fiscal Year)($5.38)

Net Income$-150,220,000.00

Net Margins-380.23%

Return on Equity-48.79%

Return on Assets-40.31%

Miscellaneous

Employees216

Outstanding Shares35,120,000

How to Become a New Pot Stock Millionaire

Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics Inc (NASDAQ:FPRX) announced its quarterly earnings results on Tuesday, February, 27th. The biotechnology company reported ($1.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.25. The biotechnology company earned $13.22 million during the quarter, compared to the consensus estimate of $9.86 million. Five Prime Therapeutics had a negative net margin of 380.23% and a negative return on equity of 48.79%. View Five Prime Therapeutics' Earnings History.

What price target have analysts set for FPRX?

4 analysts have issued 1 year target prices for Five Prime Therapeutics' stock. Their predictions range from $25.00 to $60.00. On average, they expect Five Prime Therapeutics' stock price to reach $46.75 in the next year. View Analyst Ratings for Five Prime Therapeutics.

What are Wall Street analysts saying about Five Prime Therapeutics stock?

Here are some recent quotes from research analysts about Five Prime Therapeutics stock:

1. According to Zacks Investment Research, "Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. " (3/2/2018)
2. Jefferies Group LLC analysts commented, "Near-term focus is on initial Ph2 data for cabiralizumab in PVNS at ASCO. Roche’s emactuzumab in PVNS showed an ~80% RR at high dose, but resulting in 2 cases of lupus per FPRX." (5/5/2017)

Who are some of Five Prime Therapeutics' key competitors?

Some companies that are related to Five Prime Therapeutics include Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA), AnaptysBio (ANAB), Medicines (MDCO), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Cambrex (CBM) and Insmed (INSM).

Who are Five Prime Therapeutics' key executives?

Five Prime Therapeutics' management team includes the folowing people:

Lewis T. Williams M.D. Ph.D., Executive Chairman of the Board (Age 67)
Aron Marc Knickerbocker MBA, President, Chief Executive Officer, Chief Operating Officer, Director (Age 47)
Marc L. Belsky, Chief Financial Officer, Senior Vice President (Age 61)
Kevin Baker Ph.D., Senior Vice President, Development Sciences (Age 56)
Helen Louise Collins M.D., Senior Vice President and Chief Medical Officer (Age 54)
Francis Willard Sarena J.D., Chief Strategy Officer and Secretary (Age 46)
Mark D. McDade, Lead Independent Director (Age 61)
Garry Nicholson, Director
Franklin M. Berger, Independent Director (Age 67)
Fred E. Cohen Ph.D. M.D., Independent Director (Age 60)

Has Five Prime Therapeutics been receiving favorable news coverage?

Media stories about FPRX stock have been trending somewhat positive on Tuesday, Accern reports. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Five Prime Therapeutics earned a media sentiment score of 0.12 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.04 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Five Prime Therapeutics?

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Five Prime Therapeutics' stock price today?

One share of FPRX stock can currently be purchased for approximately $17.00.

How big of a company is Five Prime Therapeutics?

Five Prime Therapeutics has a market capitalization of $566.78 million and generates $39.51 million in revenue each year. The biotechnology company earns $-150,220,000.00 in net income (profit) each year or ($5.38) on an earnings per share basis. Five Prime Therapeutics employs 216 workers across the globe.

How can I contact Five Prime Therapeutics?

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600.

MarketBeat Community Rating for Five Prime Therapeutics (FPRX)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		215 (Vote Outperform)
Underperform Votes:		137 (Vote Underperform)
Total Votes:		352

MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe FPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Five Prime Therapeutics (NASDAQ:FPRX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for Five Prime Therapeutics in the last 12 months. Their average twelve-month price target is $46.75, suggesting that the stock has a possible upside of 175.00%. The high price target for FPRX is $60.00 and the low price target for FPRX is $25.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$46.75	$46.75	$67.75	$56.00
Price Target Upside:	175.00% upside	151.61% upside	54.82% upside	28.79% upside

Five Prime Therapeutics (NASDAQ:FPRX) Consensus Price Target History

Price Target History for Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics (NASDAQ:FPRX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/28/2018	BMO Capital Markets	Lower Price Target	Outperform -> Outperform	$75.00 -> $60.00	Low
2/28/2018	Nomura	Lower Price Target	Buy -> Buy	$94.00 -> $25.00	High
11/6/2017	Royal Bank of Canada	Boost Price Target	Outperform -> Outperform	$41.00 -> $50.00	N/A
9/12/2017	Jefferies Group	Reiterated Rating	Buy	$52.00	High
3/24/2017	Cowen	Initiated Coverage	Outperform		High
3/1/2017	Instinet	Initiated Coverage	Buy -> Buy	$94.00	N/A
11/7/2016	Credit Suisse Group	Reiterated Rating	Buy	$54.00	N/A
10/25/2016	Citigroup	Initiated Coverage	Buy	$65.00	N/A
8/8/2016	Leerink Swann	Reiterated Rating	Outperform	$45.00 -> $58.00	N/A
5/19/2016	Oppenheimer	Reiterated Rating	Outperform	$48.00	N/A

(Data available from 4/24/2016 forward)

Five Prime Therapeutics (NASDAQ:FPRX) Earnings History and Estimates Chart

Earnings by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics (NASDAQ:FPRX) Earnings Estimates

2018 EPS Consensus Estimate: ($4.60)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.55)	($0.55)	($0.55)
Q2 2018	1	($1.33)	($1.33)	($1.33)
Q3 2018	1	($1.33)	($1.33)	($1.33)
Q4 2018	1	($1.39)	($1.39)	($1.39)

Five Prime Therapeutics (NASDAQ FPRX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
2/27/2018	Q4 2017	($1.29)	($1.04)	$9.86 million	$13.22 million	View	N/A
11/6/2017	Q3 2017	($1.3520)	($1.5450)	$16.16 million	$8.33 million	View	N/A
8/8/2017	Q2 2017	($1.15)	($1.58)	$8.32 million	$7.80 million	View	Listen
5/4/2017	Q1 2017	($0.96)	($1.21)	$6.05 million	$10.13 million	View	Listen
2/23/2017	Q4 2016	($0.57)	($0.73)	$7.09 million	$8.30 million	View	N/A
11/3/2016	Q3	($0.51)	($0.72)	$7.50 million	$6.70 million	View	N/A
8/4/2016	Q2	($0.56)	($0.49)	$6.38 million	$9.23 million	View	N/A
5/5/2016	Q1	($0.71)	($0.49)	$5.26 million	$6.50 million	View	N/A
3/10/2016	Q4	$9.67	$10.63	$354.16 million	$363.34 million	View	Listen
11/4/2015	Q315	($0.99)	($0.93)	$4.90 million	$5.90 million	View	N/A
8/6/2015	Q215	($0.44)	($0.45)	$6.92 million	$6.30 million	View	N/A
5/13/2015	Q1	($0.46)	($0.44)	$4.77 million	$4.30 million	View	Listen
3/17/2015	Q414	($0.40)	($0.55)	$5.39 million	$4.65 million	View	N/A
11/10/2014	Q3 2014	($0.40)	($0.33)	$5.22 million	$6.06 million	View	N/A
8/5/2014	Q2 14	($0.27)	($0.46)	$5.39 million	$4.98 million	View	N/A
5/8/2014	Q1 2014	($0.37)	($0.46)			View	N/A
3/25/2014	Q4	($0.40)	($0.43)	$1.52 million	$3.79 million	View	Listen
11/12/2013		($0.57)	($2.74)	$2.50 million	$3.48 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Five Prime Therapeutics (NASDAQ:FPRX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Five Prime Therapeutics (NASDAQ FPRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.40%
Institutional Ownership Percentage: 74.24%

Insider Trading History for Five Prime Therapeutics (NASDAQ:FPRX)

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics (NASDAQ FPRX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/1/2017	William R Ringo	Director	Sell	600	$45.33	$27,198.00	600
10/2/2017	William R Ringo	Director	Sell	1,800	$40.26	$72,468.00	1,200
9/28/2017	William R Ringo	Director	Sell	2,000	$38.00	$76,000.00	2,000
3/1/2017	William R Ringo	Director	Sell	500	$46.73	$23,365.00	500
2/1/2017	William R Ringo	Director	Sell	500	$46.17	$23,085.00	500
1/18/2017	Francis Willard Sarena	Insider	Sell	3,636	$47.39	$172,310.04	82,460
1/3/2017	William R Ringo	Director	Sell	500	$51.07	$25,535.00	500
12/23/2016	Lewis T Williams	CEO	Sell	30,000	$50.50	$1,515,000.00	434,047
12/1/2016	William R Ringo	Director	Sell	500	$57.72	$28,860.00	500
11/28/2016	Francis Willard Sarena	Insider	Sell	1,710	$60.14	$102,839.40	82,976
11/25/2016	Francis Willard Sarena	Insider	Sell	34,654	$60.38	$2,092,408.52	94,731
11/9/2016	Peder Jensen	Director	Sell	8,130	$55.30	$449,589.00	4,065
11/1/2016	William R Ringo	Director	Sell	500	$48.67	$24,335.00	500
10/3/2016	William R Ringo	Director	Sell	500	$52.00	$26,000.00	500
9/1/2016	William R Ringo	Director	Sell	500	$44.20	$22,100.00	500
8/1/2016	William R Ringo	Director	Sell	500	$50.77	$25,385.00	500
7/27/2016	Peder Jensen	Director	Sell	12,195	$49.50	$603,652.50	12,195
4/22/2016	Franklin M Berger	Director	Buy	5,000	$49.47	$247,350.00	81,980
4/22/2016	Marc Belsky	CFO	Sell	34,102	$50.00	$1,705,100.00	88,410
4/21/2016	Lewis T Williams	CEO	Sell	48,671	$48.05	$2,338,641.55	341,078
4/19/2016	Franklin M Berger	Director	Buy	6,090	$47.06	$286,595.40	77,890
4/15/2016	Lewis T Williams	CEO	Sell	1,405	$48.00	$67,440.00	341,933
4/14/2016	Lewis T Williams	CEO	Sell	2,725	$48.00	$130,800.00	343,253
4/6/2016	Lewis T Williams	CEO	Sell	52,801	$43.09	$2,275,195.09	366,477
4/6/2016	Marc Belsky	CFO	Sell	20,814	$45.04	$937,462.56	81,278
3/30/2016	Francis Willard Sarena	EVP	Sell	10,000	$40.01	$400,100.00	88,284
3/30/2016	Lewis T Williams	CEO	Sell	23,259	$40.02	$930,825.18	349,743
3/30/2016	Marc Belsky	CFO	Sell	13,876	$40.01	$555,178.76	85,751
3/2/2016	Lewis T Williams	CEO	Sell	23,259	$36.01	$837,556.59	363,611
2/4/2016	Lewis T. Williams	CEO	Sell	71,229	$33.35	$2,375,487.15	340,352
1/27/2016	Francis Willard Sarena	EVP	Sell	30,000	$35.22	$1,056,600.00
10/15/2015	Adage Capital Partners Gp Llc	Major Shareholder	Sell	125,000	$27.75	$3,468,750.00
10/15/2015	Lewis T. Williams	CEO	Sell	72,352	$27.24	$1,970,868.48	294,593
9/21/2015	Lewis T Williams	CEO	Sell	2,648	$22.06	$58,414.88	366,945
6/22/2015	Lewis T Williams	CEO	Sell	75,000	$24.67	$1,850,250.00
1/28/2015	Franklin M Berger	Director	Buy	25,000	$27.03	$675,750.00
1/15/2015	Franklin M Berger	Director	Buy	10,049	$26.17	$262,982.33
11/28/2014	Franklin M Berger	Director	Buy	1,951	$21.04	$41,049.04
11/4/2014	Lewis T Williams	CEO	Sell	32,603	$13.08	$426,447.24
10/30/2014	Lewis T Williams	CEO	Sell	17,397	$13.13	$228,422.61
9/23/2013	Brian G Atwood	Director	Buy	76,923	$13.00	$999,999.00

(Data available from 1/1/2013 forward)

Five Prime Therapeutics (NASDAQ FPRX) News Headlines

Source:

Date	Headline
	Five Prime Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on May 8 finance.yahoo.com - April 24 at 5:13 PM
	Immune Checkpoints Activators 2018 - Competitive Landscape, Technology and Pipeline Analysis ... www.businesswire.com - April 21 at 8:43 AM
	Five Prime Therapeutics (FPRX) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - April 18 at 11:22 PM
	Five Prime Therapeutics Inc (FPRX) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - April 18 at 5:30 PM
	Five Prime Therapeutics (FPRX) Announces Data on B7-H4 Therapeutic Antibody at 2018 AACR Annual Meeting www.streetinsider.com - April 16 at 4:58 PM
	Five Prime Therapeutics (FPRX) Lowered to "Strong Sell" at BidaskClub www.americanbankingnews.com - April 14 at 12:49 AM
	Five Prime Therapeutics (FPRX) Stock Rating Reaffirmed by Jefferies Group www.americanbankingnews.com - April 8 at 11:23 PM
	Five Prime Therapeutics (FPRX) Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - April 7 at 3:52 PM
	Five Prime Therapeutics (FPRX) Upgraded to "Outperform" by BMO Capital Markets www.americanbankingnews.com - April 7 at 12:31 PM
	Five Prime Therapeutics (FPRX) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - April 4 at 12:56 PM
	Five Prime Therapeutics Inc (NASDAQ:FPRX): Poised For Long-Term Success? finance.yahoo.com - April 3 at 5:05 PM
	ValuEngine Upgrades Five Prime Therapeutics (FPRX) to "Sell" www.americanbankingnews.com - April 3 at 3:35 PM
	Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five ... www.prnewswire.com - April 3 at 8:57 AM
	Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics' Targeted Immuno-Oncology Drug Candidate Bemarituzumab finance.yahoo.com - April 3 at 8:57 AM
	Five Prime Therapeutics (FPRX) Price Target Raised to $50.00 at Royal Bank of Canada www.americanbankingnews.com - April 1 at 8:06 PM
	Five Prime Therapeutics (FPRX) Cut to "Sell" at ValuEngine www.americanbankingnews.com - April 1 at 2:04 PM
	Five Prime Therapeutics (FPRX) Downgraded by Zacks Investment Research to "Hold" www.americanbankingnews.com - March 31 at 4:56 PM
	Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150 finance.yahoo.com - March 28 at 4:57 PM
	Five Prime Therapeutics (FPRX) Upgraded by BidaskClub to Sell www.americanbankingnews.com - March 28 at 11:26 AM
	Five Prime Therapeutics Announces Oral Presentation on FPA150 at the 2018 AACR Annual Meeting finance.yahoo.com - March 27 at 4:52 PM
	Five Prime Therapeutics (FPRX) Lowered to "Sell" at BidaskClub www.americanbankingnews.com - March 27 at 3:28 PM
	ValuEngine Lowers Five Prime Therapeutics (FPRX) to Strong Sell www.americanbankingnews.com - March 25 at 5:54 PM
	Five Prime Therapeutics Inc (FPRX) Receives Average Recommendation of "Hold" from Brokerages www.americanbankingnews.com - March 24 at 5:40 PM
	Five Prime Therapeutics (FPRX) Licenses New Drug Target to UCB - StreetInsider.com www.streetinsider.com - March 19 at 4:52 PM
	Five Prime Therapeutics Licenses New Target to UCB Originating from its Proprietary Protein Discovery Platform finance.yahoo.com - March 19 at 4:52 PM
	With A -128.66% Earnings Drop, Is Five Prime Therapeutics Inc’s (NASDAQ:FPRX) A Concern? finance.yahoo.com - March 16 at 8:54 AM
	Comparing Myokardia (MYOK) & Five Prime Therapeutics (FPRX) www.americanbankingnews.com - March 15 at 1:05 AM
	Five Prime Therapeutics Announces Executive Change - Business Wire (press release) www.businesswire.com - March 14 at 9:22 AM
	Five Prime Therapeutics (FPRX) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow seekingalpha.com - March 13 at 6:53 PM
	-$0.54 EPS Expected for Five Prime Therapeutics Inc (FPRX) This Quarter www.americanbankingnews.com - March 8 at 11:20 PM
	Five Prime Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference finance.yahoo.com - March 6 at 5:18 PM
	AWM Investment Company Inc. Boosts Holdings in Five Prime Therapeutics Inc (FPRX) www.americanbankingnews.com - March 6 at 4:45 AM
	Five Prime Therapeutics Inc (FPRX) to Post FY2022 Earnings of $0.13 Per Share, Jefferies Group Forecasts www.americanbankingnews.com - March 5 at 9:50 AM
	Five Prime Therapeutics Inc (FPRX) to Post Q1 2018 Earnings of ($0.55) Per Share, Leerink Swann Forecasts www.americanbankingnews.com - March 5 at 2:22 AM
	Five Prime Therapeutics (FPRX) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - March 2 at 10:52 PM
	Altrinsic Global Advisors LLC Takes Position in Five Prime Therapeutics Inc (FPRX) www.americanbankingnews.com - March 2 at 4:10 AM
	Five Prime Therapeutics' (FPRX) CEO Aron Knickerbocker on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - March 1 at 8:39 AM
	Five Prime Therapeutics (FPRX) Price Target Lowered to $25.00 at Nomura www.americanbankingnews.com - February 28 at 7:58 PM
	Five Prime Therapeutics, Inc. 2017 Q4 - Results - Earnings Call Slides seekingalpha.com - February 28 at 5:36 PM
	BMO Capital Markets Trims Five Prime Therapeutics (FPRX) Target Price to $60.00 www.americanbankingnews.com - February 28 at 11:26 AM
	Five Prime Therapeutics Inc (FPRX) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - February 27 at 7:46 PM
	Five Prime Therapeutics beats by $0.27, misses on revenue seekingalpha.com - February 27 at 5:31 PM
	Five Prime Announces Fourth Quarter and Full Year 2017 Financial Results finance.yahoo.com - February 27 at 5:31 PM
	A Six-Pack of Biotech Bets finance.yahoo.com - February 22 at 8:47 AM
	$9.86 Million in Sales Expected for Five Prime Therapeutics Inc (FPRX) This Quarter www.americanbankingnews.com - February 22 at 8:32 AM
	Five Prime Therapeutics Inc (FPRX) Expected to Post Earnings of -$1.29 Per Share www.americanbankingnews.com - February 20 at 5:14 AM
	Five Prime Therapeutics (FPRX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow seekingalpha.com - February 15 at 5:01 PM
	Five Prime Therapeutics (FPRX) Downgraded to Sell at Zacks Investment Research www.americanbankingnews.com - February 14 at 11:42 PM
	Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27 finance.yahoo.com - February 14 at 9:35 AM
	An Intrinsic Value Calculation For Five Prime Therapeutics Inc (NASDAQ:FPRX) Shows It’s 42.22% Undervalued finance.yahoo.com - February 14 at 9:35 AM

Five Prime Therapeutics (NASDAQ:FPRX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Five Prime Therapeutics (NASDAQ:FPRX) Income Statement, Balance Sheet and Cash Flow Statement

Five Prime Therapeutics (NASDAQ FPRX) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff